
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 6-K

**REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**
For the Month of September 2026
(Commission File No. 001-41636)

Oculus Holding AG

(Translation of registrant's name into English)

**Bahnhofstrasse 20
CH-6300
Zug, Switzerland**
(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On September 30, 2026, Oculis Holding AG announced the resignation of Lionel Carnot from the Board of Directors. The press release is furnished hereto as Exhibit 99.1.

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release dated September 30, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

OCULIS HOLDING AG

Date: September 30, 2026

By:

Sylvia Cheung
Chief Financial Officer



Oculis Announces Resignation of Lionel Carnot from Board of Directors

ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) ("Oculis" or the "Company"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017.

Anthony Rosenberg, Chair of the Board, remarked: "On behalf of the Board and the entire Oculis team, we wish to extend our sincere gratitude to Lionel for his invaluable service, leadership and guidance over nearly a decade, covering a transformative period for Oculis, where it evolved from a private startup company to a publicly listed late-stage biopharmaceutical company. His contributions to the Board and Oculis have been instrumental in our growth and evolution to become an emerging leader in neuro-ophthalmology."

Lionel Carnot remarked: "It has been a privilege to work alongside Oculis' talented and dedicated team committed to addressing significant unmet medical needs and advance innovative solutions for patients suffering from ophthalmic and neuro-ophthalmic diseases. As the Company enters its next stage of growth, this is a timely point for me to step down and focus on other commitments. As an investor, I remain confident in the potential of Oculis' pipeline and look forward to the Company achieving important milestones in the years ahead."

Mr. Carnot's departure is purely a personal decision and is not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices. Following the resignation, the Board will consist of eight members and the Remuneration Committee, of which Mr. Lionel served as chair, will consist of Geraldine O'Keeffe as chair and Gregory Perry and Robert Warner as members. Pursuant to Swiss law, the vacancy on the Board resulting from Mr. Carnot's resignation may only be filled at a future annual or special general meeting. Oculis will begin identifying a successor for Mr. Carnot and will provide updates as appropriate.

-ENDS-

About Oculis

Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology. Oculis' highly differentiated late-stage clinical pipeline focuses on two core product candidates. Privosegtor is a breakthrough neuroprotective candidate in the PIONEER program, which consists of studies intended to support registration plans for treatment of optic neuropathies, including optic neuritis (ON) and non-arteritic anterior ischemic optic neuropathy (NAION). Privosegtor also has potential to be developed for additional indications in other neuro-ophthalmic and neuro-axonal diseases. Licaminlimab is a novel, topical anti-TNF α in a registrational trial, and is being developed with a genotype-based approach for treating patients with dry eye disease (DED). Headquartered in Switzerland with operations in the U.S., Iceland and Switzerland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.

For more information, please visit:

**Oculis Contact**

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor Relations

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com

Media Relations

ICR Healthcare
Amber Fennell
oculis@icrhealthcare.com
